Drugs for Pollen Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 66)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Histamine |
Approved, Investigational |
Phase 4 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Β-imidazolyl-4-ethylamine
|
|
2 |
|
Fluticasone |
Approved, Experimental |
Phase 4 |
|
90566-53-3 |
4659387 5311101 |
Synonyms:
ADVAIR
Advair®|Avamys®|Flovent HFA®|Veramyst®
FLOVENT HFA
Fluticason
|
Fluticasona
Fluticasone
Fluticasonum
VERAMYST
|
|
3 |
|
Cetirizine |
Approved |
Phase 4 |
|
83881-51-0 |
2678 |
Synonyms:
(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid
(2-{4-[(4-CHLOROPHENYL)(PHENYL)METHYL]PIPERAZIN-1-YL}ETHOXY)ACETIC ACID
AC-170
Alerlisin
Aliud brand OF cetirizine dihydrochloride
Alpharma brand OF cetirizine dihydrochloride
AWD.pharma brand OF cetirizine dihydrochloride
Azupharma brand OF cetirizine dihydrochloride
Basics brand OF cetirizine dihydrochloride
Benaday
Cetalerg
Ceterifug
Ceti tad
Cetiderm
Cetidura
Cetil von CT
CetiLich
Ceti-puren
Cetirigamma
Cetirizin
Cetirizin al
Cetirizin azu
Cetirizin basics
Cetirizina
CETIRIZINE
Cetirizine dihydrochloride
Cetirizine hydrochloride
Cetirizinum
Cetirlan
|
CT-Arzneimittel brand OF cetirizine dihydrochloride
Dermapharm brand OF cetirizine dihydrochloride
Dihydrochloride, cetirizine
glaxo Wellcome brand OF cetirizine dihydrochloride
Humex
Krewel brand OF cetirizine dihydrochloride
Lacer brand OF cetirizine dihydrochloride
Lichtenstein brand OF cetirizine dihydrochloride
Menarini brand OF cetirizine dihydrochloride
Merck dura brand OF cetirizine dihydrochloride
Pfizer brand OF cetirizine dihydrochloride
Pfizer consumer healthcare brand OF cetirizine dihydrochloride
Reactine
Reactine®|Zyrtec®
Rodleben brand OF cetirizine
Sanofi synthelabo brand OF cetirizine dihydrochloride
TAD brand OF cetirizine dihydrochloride
UCB brand OF cetirizine dihydrochloride
UCB pharma brand OF cetirizine dihydrochloride
United drug brand OF cetirizine dihydrochloride
Virlix
Voltric
Wolff brand OF cetirizine dihydrochloride
Wörwag brand OF cetirizine dihydrochloride
Zetir
Zirtek
Zyrlex
Zyrtec
|
|
4 |
|
Loratadine |
Approved, Investigational |
Phase 4 |
|
79794-75-5 |
3957 |
Synonyms:
4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester
Alavert
Amantadine
Anhissen
Bonalerg
CHILDREN'S CLARITIN
Claritin
CLARITIN HIVES RELIEF
CLARITIN HIVES RELIEF REDITAB
CLARITIN REDITABS
Claritin®|SCH-29851
CLARITIN-D
Claritine
Clarityn
CLARITYN RAPIDE
Clarityne
Clarium
Cronopen
Flonidan
|
Fristamin
HAY-RITE
Histaloran
Klaritin
Lertamine
Lisino
Loracert
Loradex
Loranox
Lorastine
Loratadina
Loratadine
LORATADINE REDIDOSE
Loratadine wyeth brand
Loratadinum
Loratidine
ROLETRA
SCH-29851
Wyeth brand OF loratadine
|
|
5 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 4 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
6 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 4 |
|
52-21-1 |
|
Synonyms:
ECONOPRED
FLO-PRED
METICORTELONE
NSC-10966
OMNIPRED
PRED FORTE
|
PRED FTE
PRED MILD
PREDNISOLONE 21-ACETATE
PREDNISOLONE ACETATE
STERANE
ULTRACORTENOL
|
|
7 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4 |
|
50-24-8 |
4894 5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11Β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Codelcortone
Co-Hydeltra
Cordrol
CORTALONE
Cotogesic
Cotolone
Decaprednil
Decortin H
DEKOTIL
Delcortol
Delta F
Delta(1)-Dehydrocortisol
Delta(1)-Dehydrohydrocortisone
Delta(1)-Hydrocortisone
DELTA.1-CORTISOL
DELTA.1-Cortisol|Orapred®|Pediapred®
Delta-Cortef
Deltacortenol
DELTACORTRIL
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
Deltahydrocortisone
DELTALONE
Deltasolone
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
DESOWEN
Dexa-Cortidelt Hostacortin H
Di adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Dicortol
DILACORT
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
FERNISOLONE-P
Flamasone
Hostacortin H
HYDELTRA
Hydeltrasol
HYDELTRA-TBA
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
IMS904
Inflamase Forte
Inflamase Mild
I-Pred
Key-Pred
Klismacort
Lentosone
Lite Pred
Medrol
|
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
METICORTELONE
METI-DERM
Metreton
M-Predrol
NEO-DELTA-CORTEF
Nisolone
Nor-Pred T.B.A.
NSC-9120
NSC-9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
ORAPRED
Panafcortelone
Paracortol
Paracotol
PEDIAPRED
PEVANTI
POLY-PRED
PRDL
Precortalon
Precortancyl
Precortilon
PRECORTISYL
PRECORTISYL FTE
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
PREDL
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone acetate
Prednisolone sodium phosphate
Prednisolone tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
PRELONE
Prenolone
Rolisone
SCHERIPROCT
Scherisolon
SERVISONE
Solone
Steran
STERANE
Sterolone
Supercortisol
TRIDESILON
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
VERDESO
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
8 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 4 |
|
2921-57-5 |
1875 |
Synonyms:
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinic acid
|
Methylprednisolone hydrogen succinate
Methylprednisolone succinate
|
|
9 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4 |
|
83-43-2 |
4159 6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
6 Methylprednisolone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
Artisone-Wyeth
Besonia
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
Dopomedrol
Esametone
Firmacort
J3.872E
Lemod
Medesone
Medixon
Medlone 21
Medrate
Medric acid
Medrol
Medrol Adt Pak
Medrol Dosepak
Medrol®|U-67590A
Medrone
Mesopren
|
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
Nirypan
Noretona
NSC-19987
Predni N Tablinen
Promacortine
Reactenol
Sieropresol
Solomet
SOLU-MEDROL
Summicort
Suprametil
U-67590A
Urbason
Urbasone
Wyacort
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
10 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 4 |
|
2920-86-7 |
4897 |
Synonyms:
(+)-prednisolone hemisuccinate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethoxy)-4-oxobutanoate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
PREDNISOLONE HEMISUCCINATE
Prednisolone hemisuccinic acid
Prednisolone hydrogen succinate
PREDNISOLONE SUCCINATE
|
|
11 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
12 |
|
Histamine phosphate |
|
Phase 4 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
13 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
14 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
15 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
16 |
|
Xhance |
|
Phase 4 |
|
|
|
17 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
18 |
|
Histamine H1 Antagonists |
|
Phase 4 |
|
|
|
19 |
|
Histamine Antagonists |
|
Phase 4 |
|
|
|
20 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
21 |
|
Histamine H1 Antagonists, Non-Sedating |
|
Phase 4 |
|
|
|
22 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
23 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
24 |
|
Hormones |
|
Phase 4 |
|
|
|
25 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
26 |
|
Antiemetics |
|
Phase 4 |
|
|
|
27 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
28 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
29 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
30 |
|
Methylprednisolone Acetate |
|
Phase 4 |
|
|
584547 |
Synonyms:
Acetyl methylprednisolone
Acetyl-methylprednisolone
DEPMEDALONE
Depo medrol
Depo medrone
Depo-medrol
Depo-medrone
|
MEDROL ACETATE
Methylprednisolone 21 acetate
METHYLPREDNISOLONE ACETATE
Methylprednisolone acetate, (11beta,16alpha)-isomer
Methylprednisolone acetate, (11beta,16beta)-isomer
Methylprednisolone acetic acid
Methylprednisolone-21-acetate
|
|
31 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
32 |
|
Protective Agents |
|
Phase 4 |
|
|
|
33 |
|
Sorbitol |
Approved, Investigational |
Phase 3 |
|
69-65-8, 50-70-4 |
453 6251 5780 |
Synonyms:
(-)-Sorbitol
(−)-SORBITOL
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5S)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
7B5697N
ALEXITOL SODIUM
ARIDOL KIT
Baxter brand OF sorbitol
Bronchitol
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-(-)-Sorbitol
D-(−)-SORBITOL
D-Glucitol
Diakarmon
Diosmol
D-Mannitol
D-Sorbit
D-SORBITOL
D-Sorbol
Dulcite
e 420
e 421
e420
e-420
e421
e-421
Esasorb
FEMA NO. 3029
Foodol D 70
FRAXININE
GLC-Ol
Glucarine
Glucitol
g-Ol
Hexahydroxyhexane
Hexanhexol
INS NO.421
INS-421
Invenex
ISOMALT IMPURITY, MANNITOL-
ISOMALT IMPURITY, SORBITOL-
Isotol
Karion
Karion instant
Klysma sorbit
Kyowa powder 50m
L-Gulitol
Manicol
MANITOL
Maniton S
Maniton-S
Manna sugar
Mannazucker
Mannidex
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
MANNITOLUM
|
Mannogem 2080
Marine crystal
Medefield brand OF sorbitol
Medevac
Multitol
Mushroom sugar
Neosorb
Neosorb 20/60dC
Neosorb 70/02
Neosorb 70/70
Neosorb p 20/60
Neosorb p 60
Neosorb p 60W
Nivitin
NSC-25944
NSC-407017
Osmitrol
Osmofundin
Osmosal
Pfizer brand OF sorbitol
Resectisol
Resulax
SDM No. 35
Sionit
Sionit K
Sionite
Sionon
Siosan
Sorbex m
Sorbex R
Sorbex RP
Sorbex S
Sorbex X
Sorbilande
Sorbilax
Sorbit
Sorbit D 70
Sorbit DP
Sorbit DP 50
Sorbit D-powder
Sorbit kyowa powder 50m
Sorbit L 70
Sorbit S
Sorbit T 70
Sorbit W 70
Sorbit WP
Sorbit W-powder
Sorbit W-powder 50
Sorbite
SORBITOL
Sorbitol 3% in plastic container
Sorbitol F
Sorbitol FK
Sorbitol FP
Sorbitol pfizer brand
Sorbitol S
Sorbitol syrup C
Sorbitur
Sorbo
Sorbogem 712
Sorbol
Sorbostyl
Tobrex
Trommsdorff brand OF sorbitol
Yal
|
|
34 |
|
Ciclesonide |
Approved, Investigational |
Phase 3 |
|
126544-47-6, 141845-82-1 |
444033 6918155 |
Synonyms:
(R)-11B,16A,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE CYCLIC 16,17-ACETAL WITH CYCLOHEXANECARBOXALDEHYDE 21-ISOBUTYRATE
(R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
2-[(1S,2S,4R,8S,9S,11S,12S,13R)-6-Cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0,.0,.0,]icosa-14,17-dien-8-yl]-2-oxoethyl 2-methylpropanoic acid
2-[(1S,2S,4R,8S,9S,11S,12S,13R)-6-Cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-8-yl]-2-oxoethyl 2-methylpropanoic acid
Alvesco
ALVESCO 160
ALVESCO 80
|
Alvesco®|Omnaris®|RPR-251526
BI54903
Ciclesonida
CICLESONIDE
Omnaris
RPR-251526
ZETONNA
|
|
35 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 3 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
36 |
|
Glutaral |
Experimental |
Phase 3 |
|
111-30-8 |
3485 |
Synonyms:
1,3-Diformyl propane
1,3-Diformylpropane
1,5-Pentanedial
1,5-Pentanedione
Aldehyd glutarowy
Aldesan
Aldesen
Alhydex
Aqucar
Bactron K31
Bioglan brand OF glutaral
Bode brand OF glutaral
Cahill may roberts brand OF glutaral
Cidex
Cidex 7
Coldcide-25 microbiocide
Dermal brand OF glutaral
Dermatech brand OF glutaral
Dioxopentane
Diswart
Ecolab brand OF glutaral
Gludesin
Glutaclean
Glutaral
Glutaral(usan)
Glutaral, inn, usan
Glutaraldehyd
Glutaraldehyde
GLUTARALDEHYDE, 25% soln
Glutaralum
Glutarate dialdehyde
Glutardialdehyde
Glutarex 28
Glutaric acid dialdehyde
|
Glutaric aldehyde
Glutaric dialdehyde
Glutarol
Glutarol-1,5-pentanedial
Gluteraldehyde
Glutural
Hospex
Johnson and johnson brand OF glutaral
Korsolex
Novaruca
Pentane-1,5-dial
PENTANEDIAL
Pentanedial, homopolymer
Poly(glutaraldehyde)
Polyglutaraldehyde
Potentiated acid glutaraldehyde
Protectol gda, GT 50
PTD
Relugan GT
Relugan GT 50
Relugan GTW
Sekumatic
Sonacide
Sporicidin
Sterihyde
Sterihyde L
Ucarcide
Ucarcide 225
Ucarcide 250
Ucarset
Verucasep
Veruca-sep
Virsal
|
|
37 |
|
Salmeterol Xinafoate |
|
Phase 3 |
|
94749-08-3 |
|
Synonyms:
GR-33343 G
GR-33343-G
GR-33343X
LIPO-202
|
SALMETEROL 1-HYDROXY-2-NAPHTHOATE
SALMETEROL XINAFOATE
SEREVENT
|
|
38 |
|
Beclomethasone |
|
Phase 3 |
|
|
2308 20469 |
Synonyms:
BECLOMETASONE
BECLOMETHASONE
|
beclomethasone|SCH-18020W
|
|
39 |
|
Vaccines |
|
Phase 3 |
|
|
|
40 |
|
Omalizumab |
Approved, Investigational |
Phase 2 |
|
242138-07-4 |
|
Synonyms:
IG GAMMA-1 CHAIN C REGION
IGE025
IGE25
IGE25|olizumab|R03DX05|RG-3648|rhumab-E25|Xolair®
OLIZUMAB
|
OMALIZUMAB
RG-3648
RHUMAB-E25
XOLAIR
|
|
41 |
|
Coal tar |
Approved |
Phase 2 |
|
8007-45-2 |
|
Synonyms:
|
42 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
43 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
44 |
|
Immunoglobulin E |
|
Phase 2 |
|
|
|
45 |
|
Acidophilus |
|
Phase 1, Phase 2 |
|
|
|
46 |
|
Bifidobacterium |
|
Phase 1, Phase 2 |
|
|
|
47 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
48 |
|
Antibodies |
|
Phase 2 |
|
|
|
49 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
50 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 74)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose. |
Completed |
NCT00150514 |
Phase 4 |
Oralgen |
2 |
Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy |
Completed |
NCT00891436 |
Phase 4 |
Fluticasone furoate nasal spray;Placebo nasal spray |
3 |
Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) |
Completed |
NCT02932774 |
Phase 4 |
Cetirizine;Loratadine |
4 |
Is the Effect of Systemic Steroids Treating Pollen Induced Allergic Rhinitis Mainly Due to a Placebo Effect |
Active, not recruiting |
NCT04622917 |
Phase 4 |
MethylPREDNISolone 40 Mg/mL Injectable Suspension;NaCl 9 MG/ML Injectable Solution |
5 |
A Multicentre, International, Randomised, Double-blind, Placebo-controlled Study to Demonstrate the Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis |
Unknown status |
NCT03724240 |
Phase 3 |
|
6 |
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis |
Completed |
NCT00773240 |
Phase 3 |
Grazax;placebo |
7 |
A Multicentre, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-mixture in Patients With Clinically Relevant Grass Pollen Sensitivity. |
Completed |
NCT00264459 |
Phase 3 |
|
8 |
A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1 |
Completed |
NCT00309062 |
Phase 3 |
|
9 |
A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens |
Completed |
NCT00263627 |
Phase 3 |
|
10 |
A Multicentre, Placebo Controlled, Double-Blind Study for Evaluation of Safety and Efficacy of Preseasonal Specific Immunotherapy With an Allergoid Preparation of an Extract of a 6 Grass Pollen Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity |
Completed |
NCT00263601 |
Phase 3 |
|
11 |
Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy in Patients With Ragweed Pollinosis: a Phase III Randomized and Controlled Clinical Study |
Completed |
NCT01500642 |
Phase 3 |
|
12 |
A Nasally Applied Cellulose Powder in Seasonal Allergic Rhinitis in Adults With Grass Pollen Allergy: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study |
Completed |
NCT03039816 |
Phase 2, Phase 3 |
|
13 |
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Clinical Trial Designed to Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, 200µg, 100µg or 25µg Once Daily for Six Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age. |
Completed |
NCT00658918 |
Phase 3 |
Ciclesonide nasal;Placebo |
14 |
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200µg Once Daily) in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 12 Years and Older |
Completed |
NCT00659841 |
Phase 3 |
Ciclesonide;Placebo |
15 |
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mcg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older |
Completed |
NCT00384475 |
Phase 3 |
Ciclesonide Nasal Spray |
16 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older |
Completed |
NCT00659594 |
Phase 3 |
Ciclesonide;Placebo |
17 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older |
Completed |
NCT00659503 |
Phase 3 |
Ciclesonide;Placebo |
18 |
A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis |
Completed |
NCT02560948 |
Phase 3 |
|
19 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age |
Completed |
NCT00163514 |
Phase 3 |
Ciclesonide |
20 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age |
Completed |
NCT00261287 |
Phase 3 |
Ciclesonide |
21 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age |
Completed |
NCT00305487 |
Phase 3 |
Ciclesonide nasal spray |
22 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older |
Completed |
NCT00163501 |
Phase 3 |
Ciclesonide |
23 |
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Fluticasone Propionate/Salmeterol (FP/SAL) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR) |
Completed |
NCT00163488 |
Phase 3 |
Ciclesonide |
24 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Hydrofluoroalkane (BDP HFA) Nasal Aerosol in Subjects 12 Years of Age and Older With SAR |
Completed |
NCT01024608 |
Phase 3 |
Beclomethasone dipropionate;Placebo Nasal Aerosol |
25 |
Prospective, Randomized, Placebo-controlled, Multi-center Trial Comparing the Efficacy and Safety of Subcutaneous Immunotherapy With a Mixture of Grasses and Mites at Adequate Doses Versus Monotherapy, for the Treatment of Allergy |
Recruiting |
NCT04874714 |
Phase 3 |
|
26 |
Two Center Evaluation of the Safety and Efficacy of Topical Nasal rEV131 Versus rEV131 Vehicle (Placebo)in the Prevention of the Signs and Symptoms of Allergic Rhinitis Induced by Nasal Allergen Challenge |
Unknown status |
NCT00247520 |
Phase 1, Phase 2 |
topical nasal rEV131 |
27 |
A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy in Grass and/or Tree Pollen Allergic Subjects by Intralymphatic Allergen Administration |
Completed |
NCT00470457 |
Phase 2 |
|
28 |
SUBLIVAC® Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study |
Completed |
NCT00932607 |
Phase 2 |
sublingual immunotherapy |
29 |
A Dose-response Evaluation of ALK Tree AIT |
Completed |
NCT01675791 |
Phase 2 |
|
30 |
A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen |
Completed |
NCT00266526 |
Phase 2 |
|
31 |
Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis |
Completed |
NCT01445002 |
Phase 2 |
|
32 |
Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy |
Completed |
NCT01449786 |
Phase 2 |
rMal d 1;rBet v 1 |
33 |
Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy |
Completed |
NCT01538979 |
Phase 2 |
|
34 |
Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis |
Completed |
NCT01308021 |
Phase 2 |
|
35 |
Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy |
Completed |
NCT02654223 |
Phase 2 |
|
36 |
A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy |
Completed |
NCT00818181 |
Phase 2 |
Biological: AL0206st |
37 |
Probiotic Intervention for Children With Birch Pollen Allergy |
Completed |
NCT00746226 |
Phase 1, Phase 2 |
|
38 |
Explorative Analysis of the Immunomodulatory Capacities of Apathogenic Escherichia Coli Nissle 1917 in Patients With Rhinoconjunctivitis Due to Grass Pollen Allergy |
Completed |
NCT01013259 |
Phase 2 |
Mutaflor;Placebo |
39 |
Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy |
Completed |
NCT00293904 |
Phase 1, Phase 2 |
|
40 |
Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM Administered Subcutaneously to Hay Fever Patients |
Completed |
NCT02156791 |
Phase 2 |
|
41 |
Safety, Clinical Tolerability and Immunogenicity of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Either Alone or in Presence of DnaK Immunoregulating Adjuvant |
Completed |
NCT01506375 |
Phase 2 |
|
42 |
A Randomized, Double-blind, Placebo-controlled, 5-arm Parallel Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Steady State Efficacy of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in the Treatment of the Symptoms of Seasonal Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Mode |
Completed |
NCT00574210 |
Phase 2 |
Bilastine;Placebo |
43 |
A Multi-Center Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in The Treatment of the Symptoms of Seasonal Allergic Rhino-Conjunctivitis With Allergy to Mountain Cedar Pollen |
Completed |
NCT00574379 |
Phase 2 |
Bilastine;Placebo |
44 |
Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD) |
Completed |
NCT00078195 |
Phase 2 |
|
45 |
Grass Pollen Sublingual Tablet Immunotherapy Plus Dupilumab for Induction of Tolerance in Adults With Moderate to Severe Seasonal Allergic Rhinitis (ITN084AD) |
Recruiting |
NCT04502966 |
Phase 2 |
Dupixent® Placebo;Grazax® Placebo |
46 |
Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy |
Recruiting |
NCT03776643 |
Phase 2 |
ILT-101 ld-(IL2) |
47 |
A Double Blind Study to Investigate the Clinical Efficacy and Safety of TreeMATAMPL (Allergy Therapeutics, (UK) Ltd.), TreeMATA (Allergy Therapeutics, (UK) Ltd.) and Placebo in Patients With Seasonal Allergic Rhinitis Due to Birch Pollen Allergy, in an Environmental Exposure Chamber (EEC) Model When Exposed to Birch Pollen and Oak Pollen |
Terminated |
NCT00387478 |
Phase 2 |
|
48 |
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous Immunotherapy With DM-101 in Adults With Birch Pollen Allergy |
Completed |
NCT04266028 |
Phase 1 |
|
49 |
A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability and Immunological Effects of BM41 Compared to Placebo and to Treatment With Standard Subcutaneous Immunotherapy (as Open Comparator) in Patients With Moderate to Severe Allergic Rhinitis/ Rhino-conjunctivitis Caused by Birch Pollen |
Completed |
NCT04912076 |
Phase 1 |
BM41;ALK Alutard SQ Betula verrucosa |
50 |
Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutaneous Allergen Exposure |
Completed |
NCT01628484 |
Phase 1 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
desloratadine
levocetirizine
|
levocetirizine dihydrochloride
|
|